果蝇EZH2与乳腺癌分子分型及临床病理特征的关系

Correlations of enhancer of Drosophila zeste homolog 2 with molecular subtypes and clinicopathological parameters of breast cancer

目的探讨果蝇Zeste基因增强子人类同源物2(EZH2)与乳腺癌分子分型及临床病理参数的关系。方法根据新型乳腺癌分子分型标准,将乳腺癌进行分子分型;免疫组织化学方法检测乳腺癌组织石蜡切片中EZH2的表达;采用χ~2检验分析EZH2表达与乳腺癌新型分子分型,以及临床病理参数之间的关系;采用KaplanMeier法分析EZH2表达与乳腺癌患者无病生存率(DFS)的关系。结果 13例管腔上皮A型乳腺癌患者中,3例为EZH2高表达(23.08%);10例管腔上皮B型乳腺癌患者中,5例为EZH2高表达(50.00%);7例人表皮生长因子受体2过表达型乳腺癌患者中,3例为EZH2高表达(42.86%);12例三阴性型乳腺癌患者中,10例为EZH2高表达(83.33%)。乳腺癌各分子亚型间EZH2表达的比较,差异有统计学意义(P<0.05)。EZH2高表达与EZH2低表达患者DFS比较,差异有统计学意义(P<0.05)。结论 EZH2可能是预测乳腺癌预后的指标之一。

Objective To investigate the correlations of enhancer of Drosophila zeste homolog 2 （EZH2） with molecular subtypes and clinicopathological parameters of breast cancer. Methods The breast cancers were classified into several molecular subtypes, according to the new standard of molecular classification of breast cancer. The expression of EZH2 in paraffin sections of breast cancer tissues was tested through immunohistochemistry method. The correlations of EZH2 with clinicopathological parameters and new molecular subtypes of breast cancers were analyzed and compared through Chi-square test. The correlation between EZH2 and disease-free survival of the breast cancer patients was analyzed through Kaplan-Meier method. Results In the 13 cases of Luminal A subtype, 3 cases had high EZH2 expression （23.08%）. In the 10 cases of Luminal B subtype, 5 cases had high EZH2 expression （50.00%）. In the 7 cases of Her-2 over-expression subtype, there were 3 cases of high EZH2 expression （42.86%）. In the 12 cases of triple-negative breast cancer subtype, there were 10 cases of high EZH2 expression （83.33%）. Significant differences existed in the expression of EZH2 among the four groups of molecular subtypes of breast cancer （P〈 0.05）. There was significant difference in the disease-free survival between the breast cancer patients with high EZH2 expression and those with low EZH2 expression （P〈0.05）. Conclusions EZH2 might be one of the indexes to predict the prognosis of breast cancer.